Sarepta

FDA

Sarepta crosses the finish line with DMD med Exondys

Sarepta Therapeutics has been waiting, hoping and lobbying for approval of its Duchenne muscular dystophy drug eteplirsen for years. And now--despite intra-agency argument at the FDA and a thumbs down from the agency's expert advisers--it’s cleared for launch.